The Dual Role of Treg in Cancer

Scandinavian Journal of Immunology

Volumn 86, Issue 6, 2017, Pages 436-443

  Frydrychowicz, M ^a   Boruczkowski, M ^a   Kolecka Bednarczyk, A ^a   Dworacki, G ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR FOXP3; AUTOANTIGEN; CANCER VACCINE; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN;

HUMAN; MALIGNANT NEOPLASM; PHENOTYPE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; IMMUNOMODULATION; IMMUNOTHERAPY; MALE; METABOLISM; NEOPLASM; PROCEDURES; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

AUTOANTIGENS; CANCER VACCINES; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNE TOLERANCE; IMMUNOMODULATION; IMMUNOTHERAPY; MALE; NEOPLASMS; T-LYMPHOCYTES, REGULATORY; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

EID: 85034988159     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/sji.12615     Document Type: Review

References (102)

1. Koczorowski M, Jutel M. Human T regulatory cells: on the way to cognition. Arch Immunol Ther Exp 2013;61:229–36.
2. (+) suppressor T cells. J Exp Med 2001;193:F41–6.
3. Jonuleit H, Schmidt E. The regulatory T cell family: distinct subsets and their interrelations. J Immunol 2003;171:6323–7.
4. Whiteside TL. Regulatory T cell subsets in human cancer: are they regulating for or against tumor progression? Cancer Immunol Immunother 2014;63:67–72.
5. Ruhnau J, Schulze J, von Sarnowski B et al. Reduced numbers and impaired function of regulatory T cells in peripheral blood of ischemic stroke patients. Mediators Inflamm 2016;2016:2974605.
6. + CD4+ regulatory T cells: their knows and unknowns. Immunol Cell Biol 2011;89:346–51.
7. Pacholczyk R, Ignatowicz H, Kraj P, Ignatowicz L. Origin and T cell receptor diversity of Foxp3+CD4+CD25+ T cells. Immunity 2006;25:249–59.
8. + regulatory T cells: thymus or periphery. J Clin Invest 2003;112:1310–2.
9. Lohr J, Knoechel B, Abbas AK. Regulatory T cells in the periphery. Immunol Rev 2006;212:149–62.
10. Akbar AN, Vukmanovic-Stejic M, Taams LS, Macallan DC. The dynamic co-evolution of memory and regulatory CD4+ T cells in the periphery. Nat Rev Immunol 2007;7:231–7.
11. Whiteside TL. What are regulatory T cells (Treg) regulating in cancer and why? Semin Cancer Biol 2012;22:327–34.
12. Raimondi G, Turner MS, Thomson AW, Morel PA. Naturally occurring regulatory T cells: recent insights in health and disease. Crit Rev Immunol 2007;27:61–95.
13. (+) T cells with regulatory properties isolated from peripheral blood. J Exp Med 2001;193:1285–94.
14. Bergmann C, Strauss L, Wang Y et al. T regulatory type 1 cells (Tr1) in squamous cell carcinoma of the head and neck: mechanisms of suppression and expansion in advanced disease. Clin Cancer Res 2008;14:3706–15.
15. Roncarolo MG, Bacchetta R, Bordignon C, Narula S, Levings MK. Type 1 T regulatory cells. Immunol Rev 2001;182:68–79.
16. Bergmann C, Strauss L, Zeidler R, Lang S, Whiteside TL. Expansion of human T regulatory type 1 cells in the microenvironment of cyclooxygenase 2 overexpressing head and neck squamous cell carcinoma. Cancer Res 2007;67:8865–73.
17. + T regulatory cells, immunotherapy of cancer, and interleukin-2. J Immunother 2005;28:120–8.
18. Gregori S, Passerini L, Roncarolo MG. Clinical outlook for type-1 and FOXP3(+) T regulatory cell-based therapy. Front Immunol 2015;6:593.
19. + Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 2007;110:1225–32.
20. Deaglio S, Dwyer KM, Gao W et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 2007;204:1257–65.
21. Mandapathil M, Lang S, Gorelik E, Whiteside TL. Isolation of functional human regulatory T cells (Treg) from the peripheral blood based on the CD39 expression. J Immunol Methods 2009;346:55–63.
22. + T cells denotes a regulatory memory phenotype. Am J Transplant 2010;10:2410–20.
23. Whiteside TL, Schuler P, Schilling B. Induced and natural regulatory T cells in human cancer. Expert Opin Biol Ther 2012;12:1383–97.
24. (+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med 2000;192:303–10.
25. (+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity 2002;16:311–23.
26. + regulatory T cells: proteome analysis identifies galectin-10 as a novel marker essential for their anergy and suppressive function. Blood 2007;110:1550–8.
27. + regulatory T cells allows for their purification from expansion cultures. Blood 2009;113:5125–33.
28. + regulatory T cells. Proc Natl Acad Sci U S A 2009;106:13445–50.
29. Fife BT, Bluestone JA. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev 2008;224:166–82.
30. + Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV. J Clin Invest 2009;119:551–64.
31. + T regulatory cells: implications and impact on tumor-mediated immune suppression. J Immunol 2008;180:2967–80.
32. + regulatory T cells (Tregs) encompass induced Tregs that express Aiolos and respond to IL-1β by downregulating their suppressor functions. J Immunol 2013;191:4619–27.
33. −cells coexist within the natural FOXP3 + T regulatory cell subset in humans. J Immunol 2013;190:2001–8.
34. (+) T regulatory cells. Expert Opin Biol Ther 2012;12:1423–5.
35. Whiteside TL. Induced regulatory T cells in inhibitory microenvironments created by cancer. Expert Opin Biol Ther 2014;14:1411–25.
36. +-regulatory T cells from mouse to man. Scand J Immunol 2005;62:1–15.
37. Bruder D, Probst-Kepper M, Westendorf AM et al. Frontline: neuropilin-1: a surface marker of regulatory T cells. Eur J Immunol 2004;34:623–30.
38. + Treg. Eur J Immunol 2009;39:1466–71.
39. Chaudhary B, Khaled YS, Ammori BJ, Elkord E. Neuropilin 1: function and therapeutic potential in cancer. Cancer Immunol Immunother 2014;63:81–99.
40. Zoltán Fehérvári Z, Sakaguchi S. A paragon of self-tolerance: CD25 + CD4 + regulatory T cells and the control of immune responses. Arthritis Res Ther 2004;6:19–25.
41. Itoh M, Takahashi T, Sakaguchi N et al. Thymus and autoimmunity: production of CD25 + CD4 + naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic selftolerance. J Immunol 1999;162:5317–26.
42. Bystry RS, Aluvihare V, Welch KA, Kallikourdis M, Betz AG. B cells and professional APCs recruit regulatory T cells via CCL4. Nat Immunol 2001;2:1126–32.
43. + regulatory T cells. J Exp Med 2000;194:847–53.
44. Zaunders JJ, Munier ML, Seddiki N et al. High levels of human antigen-specific CD4 + T cells in peripheral blood revealed by stimulated coexpression of CD25 and CD134 (OX40). J Immunol 2009;183:2827–36.
45. Xiao X, Gong W, Demirci G et al. New insights on OX40 in the control of T cell immunity and immune tolerance in vivo. J Immunol 2012;188:892–901.
46. + naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int Immunol 1998;10:1969–80.
47. Sakaguchi S, Wing K, Miyara M. Regulatory T cells – a brief history and perspective. Eur J Immunol 2007;37:S116–23.
48. Chatila TA, Blaeser F, Ho N et al. JM2, encoding a fork head-related protein, is mutated in X-linked autoimmunity-allergic disregulation syndrome. J Clin Invest 2000;106:R75–81.
49. Wildin RS, Ramsdell F, Peake J et al. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat Genet 2001;27:18–20.
50. Bennett CL, Christie J, Ramsdell F et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 2001;27:20–1.
51. Mercer F, Unutmaz D. The biology of FoxP3: a key player in immune suppression during infections, autoimmune diseases and cancer. Adv Exp Med Biol 2009;665:47–59.
52. Torgerson TR, Ochs HD. Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome: a model of immune dysregulation. Curr Opin Allergy Clin Immunol 2002;2:481–7.
53. + regulatory T-cells. Nat Immunol 2003;4:330–6.
54. Li B, Greene MI. FOXP3 actively represses transcription by recruiting the HAT/HDAC complex. Cell Cycle 2007;6:1432–6.
55. + regulatory T-cells. Blood 2005;105:4743–8.
56. + regulatory T-cells cultured with rapamycin. J Immunol 2007;178:320–9.
57. Yong PL, Russo P, Sullivan KE. Use of sirolimus in IPEX and IPEX-like children. J Clin Immunol 2008;28:581–7.
58. Kim CH. Regulation of FoxP3 regulatory T-cells and Thl7 cells by retinoids. Clin Dev Immunol 2008;2008:416910.
59. Sun CM, Hall JA, Blank RB et al. Small intestine lamina propria dendritic cells promote de novo generation of Foxp3 Treg cells via retinoic acid. J Exp Med 2007;204:1775–85.
60. Gershwin ME, Lentz DR, Beach RS, Hurley LS. Nutritional factors and autoimmunity. IV. Dietary vitamin A deprivation induces a selective increase in IgM autoantibodies and hypergammaglobulinemia in New Zealand Black mice. J Immunol 1984;133:222–6.
61. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell 2008;133:775–87.
62. Schenk U, Frascoli M, Proietti M et al. ATP inhibits the generation and function of regulatory T cells through the activation of purinergic P2X receptors. Sci Signal 2011;4:ra12.
63. Schenk U, Westendorf AM, Radaelli E et al. Purinergic control of T cell activation by ATP released through pannexin-1 hemichannels. Sci Signal 2008;1:ra6.
64. Curiel TJ. Regulatory T cells and treatment of cancer. Curr Opin Immunol 2008;20:241–6.
65. Budna J, Kaczmarek M, Sikora J. Znaczenie komórek T regulatorowych w rozwoju tolerancji na nowotwór. Post Biol Komórki 2011;38:283–95.
66. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006;6:295–307.
67. + regulatory T cells in the peripheral blood of patients with prostate cancer. Clin Cancer Res 2008;14:1032–40.
68. + T cells predict poor survival in renal cell carcinoma. Clin Cancer Res 2007;13:2075–81.
69. Curiel TJ. Tregs and rethinking cancer immunotherapy. J Clin Invest 2007;117:1167–74.
70. + regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma. Haematologica 2008;93:193–200.
71. Carreras J. High numbers of tumor infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood 2006;108:2957–64.
72. Alvaro T, Lejeune M, Salvadó MT et al. Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res 2005;11:1467–73.
73. + T cells secreting IL-10 and TGF-beta1 mediates suppression in the tumor microenvironment. Clin Cancer Res 2007;13 (15 Pt 1):4345–54.
74. Madapathil M, Szczepanski MJ, Szajnik M et al. Increased ectonucleotidase expression and activity in regulatory T cells of patients with head and neck cancer. Clin Cancer Res 2009;15:6348–57.
75. Badoual C, Hans S, Rodriquez J et al. Prognostic value of tumor-infiltrating CD4 + T-cell subpopulations in head and neck cancers. Clin Cancer Res 2006;12:465–72.
76. (+) T cells to the antitumor immune response. J Exp Med 2005;201:1591–602.
77. Whiteside TL. Immunobiology of head and neck cancer. Cancer Metastasis Rev 2005;24:95–105.
78. Hooper SJ, Wilson MJ, Crean SJ. Exploring the link between microorganisms and oral cancer: a systematic review of the literature. Head Neck 2009;31:1228–39.
79. + Treg clones obtained from peripheral blood of patients with cancer. Int J Cancer 2007;121:2473–83.
80. (+) regulatory T cells is associated with clinical behaviour in gastric cancer. Br J Cancer 2008;98:148–53.
81. + cytotoxic T/NK cells predicts prognosis in classical Hodgkin lymphoma and is independent of bcl-2 and MAL expression. Am J Clin Pathol 2007;128:958–65.
82. +CD25 T cells. Blood 2007;110:2537–44.
83. Juszczynski P, Ouyang J, Monti S et al. The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. Proc Natl Acad Sci U S A 2007;104:13134–9.
84. + T regulatory cells: role of tumor-derived TGF-beta. J Immunol 2007;178:2883–92.
85. (−) T cells through secreting TGF-beta. Cancer Lett 2007;253:144–53.
86. + T regulatory cells. Blood 2007;109:2871–7.
87. + regulatory T cell population by non-Hodgkin's lymphoma. Blood 2008;111:5359–70.
88. (+) regulatory T cells. J Surg Res 2007;141:72–7.
89. Robbins PD, Morelli AE. Regulation of immune responses by extracellular vesicles. Nat Rev Immunol 2014;14:195–208.
90. Frydrychowicz M, Kolecka-Bednarczyk A, Madejczyk M, Yasar S, Dworacki G. Exosomes – structure, biogenesis and biological role in non-small-cell lung cancer. Scand J Immunol 2015;81:2–10.
91. Szajnik M, Czystowska M, Szczepanski MJ, Mandapathil M, Whiteside TL. Tumor-derived microvesicles induce, expand and up-regulate biological activities of human regulatory T cells (Treg). PLoS ONE 2010;5:e11469.
92. Liyanage UK, Moore TT, Joo HG et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002;169:2756–61.
93. Hwang I, Shen X, Sprent J. Direct stimulation of naive T cells by membrane vesicles form antigen-presenting cells: distinct roles for CD54 and B7 molecules. Proc Natl Acad Sci USA 2003;100:6670–5.
94. Whiteside TL. Immune modulation of T-cell and NK (natural killer) cell activities by TEXs (tumour-derived exosomes). Biochem Soc Trans 2013;41:245–51.
95. Muller L, Mitsuhashi M, Simms P, Gooding WE, Whiteside TL. Tumor-derived exosomes regulate expression of immune function-related genes in human T cell subsets. Sci Rep 2016;6:20254.
96. Iero M, Valenti R, Huber V et al. Tumour-released exosomes and their implications in cancer immunity. Cell Death Differ 2008;15:80–8.
97. Zhang HG, Grizzle WE. Exosomes and cancer: a newly described pathway of immune suppression. Clin Cancer Res 2011;17:959–64.
98. + T lymphocytes. J Immunol 2009;183:3720–30.
99. + cells. Clin Exp Immunol 2014;177:531–43.
100. neg T-cell subsets in cancer patients. Eur J Immunol 2012;42:1876–85.
101. + T cells in the circulation of patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 2007;13:6301–11.
102. Whiteside TL, Jackson EK. Adenosine and prostaglandin E2 production by human inducible regulatory T cells in health and disease. Front Immunol 2013;4:212.